Business Wire

GE Renewable Energy Launches Cypress Onshore Wind Platform, Designed to Grow, Adapt, Thrive and Lower the Cost of Electricity for Customers

Del

GE Renewable Energy (NYSE:GE) today launched its new onshore turbine platform, named Cypress, and the next model from that platform, GE’s 5.3-158 turbine. The platform advances the proven technology of GE’s 2MW and 3MW fleets, which serves an installed base of nearly 20GW, while also utilizing architecture and innovations from the 4.8-158 turbine introduced in 2017. Cypress enables significant AEP improvements, increased efficiency in serviceability, improved logistics and siting potential, and ultimately more value for customers. It is designed to scale over time, enabling GE to offer a wider array of power ratings and hub heights to meet customer needs throughout the 5MW range. The platform also offers up to a 50 percent increase in AEP over the life of the platform versus GE’s 3MW turbines. It is the second major technology platform launch of the year for GE, which introduced the Haliade-X offshore turbine platform in March.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005258/en/

Cypress enables significant AEP improvements, increased efficiency in serviceability, improved logis ...

Cypress enables significant AEP improvements, increased efficiency in serviceability, improved logistics and siting potential, and ultimately more value for customers. (Photo: Business Wire)

The Cypress platform, which also includes the 4.8-158, will be powered by a revolutionary two-piece blade design, enabling blades to be manufactured at even longer lengths and improving logistics to offer more siting options. Longer blades improve AEP and help drive down the Levelized Cost of Electricity (LCOE), and the proprietary design will allow these larger turbines to be installed in locations that were previously inaccessible. It significantly drives down logistical costs, by enabling blade assembly onsite and reducing the costs for permitting equipment and road work required for transporting longer blades. Equally importantly, it features blade tips that offer customers greater flexibility to address site wind conditions and requirements.

The high-tech carbon blades were developed through the longtime partnership between GE’s Onshore Wind business, GE’s Global Research Center and GE’s LM Wind Power, taking advantage of the research, design and large-scale manufacturing expertise of these teams to bring the blades from concept to a tested and proven reality.

The Cypress platform, designed for IEC (S) wind speeds, leverages the best of GE's 2MW and 3MW turbines – including the proven DFIG-doubly-fed induction generator – and a robust drivetrain architecture. The machine is specifically designed for services, with enhancements to help with facilitating up-tower repairs and troubleshooting with its up-tower electrical system, while also pushing the limits of traditional reliability levels on major components, through increased systems level hardware testing and more robust manufacturing processes. This combination of planned, condition-based and predictive services will help to ensure more reliability, uptime and production while ultimately lowering lifecycle costs for the customer.

Pete McCabe, CEO of GE’s Onshore Wind business said, “Our mission is to enable our customers to set the pace for lowering the LCOE around the world, as their needs continue to evolve. The Cypress platform builds on our track record of success and positions our technology for scalability and flexibility for the coming years. The prototype Cypress 4.8-158 is currently under production at our Salzbergen, Germany facility and we are looking forward to deploying and commissioning it by the end of the year. This platform, which reflects our relentless focus on quality, will enable our customers to achieve a new level of competitiveness in the power generation marketplace.”

Duncan Berry, CEO of GE’s LM Wind Power said, “This exciting blade enhancement is revolutionizing the offerings that we can provide for GE’s customers. Our team used a disruptive design methodology and customer feedback to re-examine our entire design and manufacturing process. By looking at this blade in an entirely new way, we achieved a technology breakthrough that will allow us to bring the new blades to market even faster for our customers.”

About GE Renewable Energy

GE Renewable Energy is a $10 billion business with a start-up mindset, bringing together one of the broadest energy products and digital services portfolios in the renewable energy industry. Combining onshore and offshore wind, blades, hydro and innovative technologies such as hybrid systems and concentrated solar power, GE Renewable Energy has installed more than 400+ gigawatts capacity globally to make the world work better and cleaner. With more than 22,000 employees present in more than 80 countries, GE Renewable Energy is working on new ways to power the world’s biggest economies and most remote communities.

Follow us at www.ge.com/renewableenergy or on twitter @GErenewables

Contact information

GE Renewable Energy
Sebastien Duchamp
Director, External Affairs
sebastien.duchamp@ge.com
+33 6 73 19 59 64
or
Tim Brown
timothy.s.brown@ge.com
+1-302-509-9352 (cell)

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an